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In several murine models of autoimmune arthritis, Th17 cells are
the dominant initiators of inﬂammation. In human arthritis the
majority of IL-17–secreting cells within the joint express a cytokine
phenotype intermediate between Th17 and Th1. Here we show
that Th17/1 cells from the joints of children with inﬂammatory
arthritis express high levels of both Th17 and Th1 lineage-speciﬁc
transcription factors, RORC2 and T-bet. Modeling the generation
of Th17/1 in vitro, we show that Th17 cells “convert” to Th17/1
under conditions that mimic the disease site, namely low TGFβ and
high IL-12 levels, whereas Th1 cells cannot convert to Th17. Th17/1
cells from the inﬂamed joint share T-cell receptor (TCR) clonality
with Th17 cells, suggesting a shared clonal origin between Th17
and Th17/1 cells in arthritis. Using CD161, a lectin-like receptor that
is a marker of human Th17, we show synovial Th17 and Th17/1
cells, and unexpectedly, a large proportion of Th1 cells express
CD161. We provide evidence to support a Th17 origin for Th1 cells
expressing CD161. In vitro, Th17 cells that convert to a Th1 phe-
notype maintain CD161 expression. In the joint CD161+ Th1 cells
share features with Th17 cells, with shared TCR clonality, expres-
sion of RORC2 and CCR6 and response to IL-23, although they are
IL-17 negative. We propose that the Th17 phenotype may be un-
stable and that Th17 cells may convert to Th17/1 and Th1 cells in
human arthritis. Therefore therapies targeting the induction of
Th17 cells could also attenuate Th17/1 and Th1 effector popula-
tions within the inﬂamed joint.
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Th17 cells are a recently identiﬁed CD4
+ subset with proin-
ﬂammatory actions (1) thought to be critical to the patho-
genesis of collagen-induced arthritis (CIA), a murine model of
autoimmune arthritis (2). Differentiation and stabilization of the
Th17 program is dependent on a range of cytokines, including
IL-23, a member of the IL-12 family (3, 4). Genetic ablation of
IL-23 conﬁnes Th17 numbers in vivo and prevents the induction
of CIA (2). In contrast, ablation of IL-12, which is central to Th1
differentiation, aggravates disease. Although Th17 cells are the
dominant pathogenic population in several arthritis models (5),
in human arthritis the role of Th17 is less clear. Childhood au-
toimmune arthritis, known as juvenile idiopathic arthritis (JIA),
has provided valuable insights into, and serves as a powerful in
vivo model of, the immunopathogenesis of human arthritis. We
have demonstrated a role for regulatory T cells in determining
JIA disease phenotype (6). We have also shown IL-17 to be
highly expressed in JIA synovial membrane, IL-17–secreting cells
to be enriched in the joint compared with blood, and that the
frequency of synovial Th17 cells correlates with disease severity,
suggesting a pathological role for Th17 in JIA (7). Addition-
ally, Th17 responses also show a strong association with anky-
losing spondylitis and psoriatic arthritis (8), but their link with
rheumatoid arthritis is less clear (9).
In contrast to early reports of Th17 cells as a pure IL-17–
secreting lineage (10), cells recovered from the inﬂamed joint
produce IFN-γ and express chemokine receptors that are in-
termediate in phenotype between Th1 and Th17 cells (7, 11). This
result raises questions about the ancestry and transcriptional
control of IL-17–secreting T cells in human arthritis. Recent
studies have suggested that Th17 cells may up-regulate IFN-γ and
also extinguish IL-17 in response to IL-12 or IL-23 in the absence
of TGF-β in vitro (12, 13), leading to a Th17/1 (IL-17+IFN-γ+) or
Th1 phenotype. Plasticity of Th17 cells has been demonstrated in
vivo in murine models, such that an adoptively transferred Th17
population gives rise to Th1 cells detectable at the inﬂammatory
site (13, 14). In human autoimmune disease it remains to be de-
termined if Th17/1 cells or indeed Th1 cells found in the inﬂamed
organ show evidence for a Th17 origin. The local factors leading to
a predominance of Th17/1 over Th17 in human autoimmune dis-
ease are uncertain.
Human studies have been limited by the difﬁculty in isolating
viable Th17 cells. Initial studies enriched human Th17 cells on
the basis of chemokine receptor expression and more recently,
the lectin-like receptor CD161, which identiﬁes the Th17 pre-
cursor pool in umbilical cord blood (15). In adults with inﬂam-
matory bowel disease (IBD), CD161 detects gut-resident Th17
but is not exclusive to Th17 cells, as it also marks Th17/1 and Th1
cells (16). In the present study, Th17 cells from arthritic joints
were analyzed directly ex vivo using cytokine capture technology.
We conﬁrm that Th17/1 cells from the joint share RORC2 and
T-bet expression and can be generated in vitro under conditions
that mimic the disease site, namely low TGF-β and high IL-12
levels. To test the hypothesis that Th17 converts to Th1 in human
arthritis, we analyzed T-cell receptor (TCR) clonality of synovial
T cells and demonstrate shared TCR sequence identity between
Th17 and Th1 cells, in particular Th1 cells expressing CD161.
To our knowledge this study of human arthritis is unique in
directly analyzing the transcriptional, functional, and clonal pro-
perties of Th17 and Th17/1 cells from the joint. Our results have
important implications for future therapeutic strategies such as
blockade of the Th17 population.
Results
Synovial Th17 Cells Coexpress IFN-γ and Account for the CCR4lo Phe-
notype Found Within the Joint. Original reports detailing Th17 as
a unique T-cell lineage emphasized their distinction from Th1
cells in terms of phenotype and function (10, 17). However,
a small proportion of Th17 cells coexpress the Th1 cytokine
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IFN-γ in peripheral blood of healthy adults (18). Within the
inﬂamed joints of JIA patients, this proportion is greatly increased,
with 50% of all IL-17+ CD4+ T cells coexpressing IFN-γ (here
called Th17/1 cells) (Fig. 1 A and B). As Th17/1 cells have an in-
termediate cytokine proﬁle between Th17 and Th1 cells, we in-
vestigated whether their transcriptional programming shared
elements with Th17 and Th1 cells. To enrich for Th17 and Th17/1,
we adapted a sorting strategy previously used for peripheral blood
mononuclear cells (PBMC) based on chemokine receptor expres-
sion (18). After sorting synovial ﬂuid (SF) CD4+ T cells into CCR4
−CCR6−, CCR4−CCR6+, and CCR4+CCR6+ populations, en-
richment of Th17/1 is most marked in the CCR4−CCR6+ pop-
ulation (Fig. 1C), which accounts for the CCR4lo phenotype of
synovial IL-17+ cells previously documented (7). We conﬁrmed
that “classical” Th17 cells (IL-17+IFN-γ−) from SF are most
abundant in the CCR4+CCR6+ sample (18). After in vitro stim-
ulation of sorted SF populations, cytokines released correlate
with intracellular cytokine detected by ﬂow cytometry (Fig. 1 C
and D). Transcription factor analysis showed that RORC2 mRNA
expression is elevated in both Th17 and Th17/1 enriched pop-
ulations compared with Th1 cells, suggesting overlapping tran-
scriptional control in both Th17 subsets (Fig. 1E). There is no
difference in expression of the aryl hydrocarbon receptor (AHR)
between sorted synovial populations (Fig. 1E).
Synovial Th17/1 Cells Express Both Th1 and Th17 Transcription Factors.
We used IL-17 and IFN-γ-speciﬁc capture assays to allow clear
separation of cytokine-expressing cells (Fig. S1). This assay was
used to detect Th17, Th17/1, and Th1 cells from synovial ﬂuid
mononuclear cells (SFMC), on the basis of surface-captured
cytokines and cells sorted into distinct populations (Fig. 2A).
Transcription factor expression analyses of these cell populations
showed greater expression of RORC2 mRNA in both Th17 and
Th17/1 than in Th1 cells, but no differences in IFN regulatory
factor 4 (IRF4), which has also been linked to Th17 differenti-
ation (19) (Fig. 2B). Interestingly, pure Th17/1 cells show a trend
for intermediate expression of T-bet compared with Th17 and
Th1 (Fig. 2B). We next conﬁrmed that RORC2 is detectable at
the protein level by ﬂow cytometry in Th17 and Th17/1 cells,
from blood and joint, closely mirroring mRNA expression in
SFMC (Fig. 2C).
Cytokine Microenvironment Found Within the Joint Promotes Th17
Plasticity. Our results indicate that synovial Th17/1 cells are in-
termediate between Th17 and Th1 cells in terms of cytokine pro-
duction, chemokine receptor, and transcription factor expression
(Figs. 1 and 2). Some reports suggest that the Th17/1 population
arises from Th17 but not Th1 cells, in response to IL-12 or IL-23A B
C
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Fig. 1. IL-17+ CD4+ T cells from the synovial ﬂuid of juvenile idiopathic
arthritis (JIA) patients coexpress IFN-γ. (A) Representative dot plots from
paired PBMC and SFMC from a JIA patient showing ﬂow cytometric analysis
of IL-17 and IFN-γ production after stimulation with PMA and ionomycin
in the presence of Brefeldin A. Numbers in plots indicate percentages of
cytokine-producing cells gated on lymphocytes and CD4+ T cells. (B) Coex-
pression of IFN-γ in IL-17+ CD4+ T cells taken from healthy control PBMC (n =
9), JIA PBMC (n = 17), and SFMC (n = 21). *P < 0.001. Bars represent mean
values (±SEM). (C) Synovial CD4+ T cells were sorted according to expression
of CCR4 and CCR6. Shown is IL-17 and IFN-γ production in CCR4−CCR6−,
CCR4−CCR6+, and CCR4+CCR6+ sorted populations, one representative ex-
periment of four. (D) IL-17 and IFN-γ protein detected in supernatants from
sorted populations as in C, after stimulation with PMA and ionomycin for 5 h
(n = 4). *P < 0.05. (E) mRNA expression of RORC2 and AHR in sorted pop-
ulations as in C, normalized to β2M levels, n = 6 and 4, respectively. *P < 0.05,




Fig. 2. Synovial T cells secreting IL-17 and IFN-γ express both Th1 and Th17
transcription factors. (A) IFN-γ– and IL-17–secreting CD4+ SFMC were detec-
ted by ﬂow cytometry using cytokine capture assay. Shown are represen-
tative dot plots of unsorted SFMC (Left) gated on CD4+ T cells demonstrating
surface capture of IL-17 and IFNγ and sorted by ﬂow cytometry into Th1,
Th17, and Th17/1 populations (Right three plots). Numbers in plots indicate
percentages of cells secreting cytokines. (B) RORC2, IRF4, and T-bet mRNA
expression in synovial CD4+ T-cell populations sorted as above. *P < 0.05.
Bars represent mean values (±SEM, n = 3, 4, and 4, respectively). (C) Histo-
gram of RORC2 protein expression analyzed by ﬂow cytometry in healthy
control CD4+ T cells (Left); isotype control (gray histogram), Th1 cells (dotted
line), and Th17 cells (thick solid line), representative of n = 3 are shown.
Summary is shown of RORC2 protein expression (MFI) in cytokine-expressing
subpopulations from JIA PBMC (Center) and JIA SFMC CD4+ T cells (Right).
*P < 0.05. Bars represent mean values (±SEM, n = 5).
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in the absence of TGF-β (12, 13). To test if these cytokines are
relevant to the enrichment of Th17/1 in the joint we compared
levels in the joint with levels in patients’ blood. The synovial
compartment has a distinct balance compared with plasma, with
signiﬁcantly higher levels of IL-12 and a relatively low abundance
of TGF-β (Fig. 3A). IL-23 is not detectable in either synovial
ﬂuid or plasma. To model the effects of the synovial microen-
vironment on Th17 plasticity we cultured puriﬁed Th17 (mean
purity 92.8%) from healthy control PBMC, in serum-free me-
dium, in the presence of IL-12 to reﬂect the synovial compart-
ment, or TGF-β to mimic plasma, or both cytokines. Th17 cells
rapidly up-regulate IFN-γ production and show a signiﬁcant in-
crease in the frequency of Th17/1 cells when cultured with IL-12
(Fig. 3 B and C). In contrast, the presence of TGF-β stabilizes
the Th17 phenotype, but fails to overcome the effects of IL-12
(Fig. 3 B and C). IL-12 also promotes a proportion of cells to
develop a Th1 phenotype (5.2 ± 1.9%). In murine studies IL-6
has been shown to stabilize the Th17 phenotype, partly through
trans signaling by engagement of IL-6 and sIL-6R (20). Although
IL-6 was enriched within the joint (Fig. S2A), it failed to atten-
uate the effects of IL-12 on Th17 plasticity in vitro (Fig. S2B).
Puriﬁed Th1 cells harvested directly ex vivo fail to revert to a
pure Th17 or Th17/1 phenotype in response to cytokines known
to induce Th17 in vitro (4): IL-1β, IL-23, IL-6, or IL-21 (Fig.
S2C). IL-21 was detectable in synovial ﬂuid, but was not enriched
relative to plasma (Fig. S2D).
Th17 Cells Share Clonal Ancestry with Th17/1 Cells and Th1 Cells
Within the Joint.Our results demonstrating plasticity of Th17 cells
in vitro led us to hypothesize that at the inﬂammatory site, Th17/
1 cells may originate from a Th17 but not a Th1 pool. If so, the
clonal distribution within the Th17/1 population would be more
similar to Th17 than to Th1 cells. To test this hypothesis we
separated synovial T cells into the three populations (Th17,
Th17/1, and Th1) directly ex vivo and performed analysis of the
TCR-β variable chain (TRBV) across the CDR3 junction using
spectratyping (Fig. 3D). As we have previously observed, synovial
T cells exhibit oligoclonal TCR repertoires (21). Comparing
oligoclonality patterns in the three populations showed that
typically half or more of TRBV families share oligoclonal pat-
terns between Th17 and Th17/1 cells, which are distinct from the
Th1 oligoclonal patterns. Data from two representative patients
are shown in Fig. 3D.
CD161 Expression May Identify Th1 Cells with a Th17 Ancestry. We
next investigated whether Th17 cells that may have converted in
vivo to Th1 can be identiﬁed by the surface marker CD161, the
human equivalent of murine NKR-P1A (22). CD161 has em-
erged as a potential lineage marker for Th17 cells in humans.
Overexpression of RORC2 induces CD161 expression (23), and
only CD161+ cells taken from cord blood can differentiate into
Th17 (15). Within the inﬂamed joint, we found that the majority
of synovial Th17 and Th17/1 are CD161+ve; however, Th1 cells
showed distinct CD161+ and CD161− populations (Fig. 4 A and
B). If CD161 predicts Th17 commitment in naive cord blood
T cells before IL-17 expression, we hypothesized that CD161
expression might be maintained following switch of Th17 cells to
a Th1 phenotype. To test this hypothesis, sorted CD161+ Th17
cells were cultured in the presence of IL-12 to promote plasticity
toward Th17/1 and Th1 cells (Fig. 4C). After conversion to a
Th17/1 phenotype, cells maintained CD161 expression, as did
the majority of converted Th1 cells (82 ± 5%, Fig. 4 C and D).
CD161− CD4+ T cells cultured under the same conditions failed
to up-regulate CD161 (Fig. 4D). Consistent with these in vitro
data suggesting that CD161 may identify cells within the Th1
population that have a Th17 ancestry, we found that CD161+
Th1 cells sorted from the inﬂamed joint had signiﬁcantly higher
RORC2 expression than CD161− cells despite both populations
having very low levels of IL-17 mRNA (Fig. 4E). CCR6 and
IL-23R, downstream targets of RORC2 (4), were also analyzed
in the Th1 subpopulations. CD161+ Th1 cells are enriched for
CCR6 protein expression (Fig. 4F) and IL-23R mRNA and
protein (Fig. 4G) compared with CD161− Th1 cells. To test if
CD161+ Th1 cells showed a functional response to IL-23, SFMC
Th1 cells were enriched without the capture assay, avoiding
stimulation with PMA and ionomycin (Fig. S3A). Having de-
pleted the CCR6+ population to exclude Th17 cells, CD161+
cells were still enriched for IL-23R message (Fig. S3B) and
showed a trend for increased secretion of IFN-γ and TNF-α in
response to IL-23 compared with CD161− cells (Fig. S3C).
Finally, to test the clonal relationships between Th1 CD161+
and Th17 populations in arthritis patients, we sorted synovial
Fig. 3. Th17 cells share clonal ancestry with Th17/1 cells and Th1 cells within
the joint and demonstrate plasticity in vitro. (A) IL-12 and TGF-β in JIA plasma
and synovial ﬂuid (IL-12, n = 16 and 19; and TGFβ, n = 7 and 11, respectively).
*P < 0.01, **P < 0.05. (B) Th17 cells were captured from healthy control
PBMC and cultured in serum-free medium in the presence of IL-2 or addi-
tionally with recombinant IL-12, TGF-β or both as shown. Dot plots of cyto-
kine production in Th17 cells after culture for 6 d are shown. Numbers in
plots indicate percentages of cells secreting cytokines. (C) Summary of three
independent experiments culturing puriﬁed Th17 cells as in B. Bars represent
mean number (±SEM) of cells as a percentage of live cells harvested with
resultant Th1 cells (open bars), Th17/1 cells (shaded bars), or Th17 cells (solid
bars). *P < 0.05. (D) Th17, Th17/1, and Th1 cells were sorted from SFMC using
cytokine capture assay and T-cell receptor BV (TRBV) spectratyping was
performed (n = 3). Three representative TRBV families are shown, from two
separate SFMC samples. Arrows indicate clonal peaks shared between Th17
and Th17/1 populations.









Th1 cells by CD161 expression and compared their TRBV with
those of IL-17+ synovial T cells (Fig. S3D). PCR products from
one BV subfamily (patient 1, BV18) were cloned and sequenced.
In this sample, the unique TCR sequences of CD161+ and
CD161− cells within the IFN-γ+ population are distinct (Fig. 4H
and Table S1). However, interestingly speciﬁc TRBV CDR3
sequences were identiﬁed that are shared between IL-17+ cells
and the CD161+IFNγ population, but these clones were not
detected in the CD161− cells. These data suggest that at least
a proportion of T cells within the CD161+ IFN-γ population
share a common ancestral clonality with Th17 cells.
Discussion
Following the identiﬁcation of Th17 cells, evidence from several
models of autoimmune arthritis led to a shift in assigning disease
pathogenesis from Th1 to Th17 cells (2, 5). However, in the
inﬂamed joints of patients with childhood arthritis, we show here
that the majority of IL-17+ cells are polyfunctional, coexpressing
IFN-γ. We examined the relationship between Th17/1 and
“pure” Th17 and Th1 cells from the joint and show links in terms
of transcriptional control, plasticity in vitro, and evidence that
supports the concept of shared ancestry between Th17 and Th1
cells expressing CD161.
In the inﬂamed site, both Th17 and Th17/1 cells are restricted
to the CCR6 compartment, which may reﬂect the dominant role
of CCL20, a CCR6 ligand, in the recruitment of IL-17+ cells to
the inﬂammatory site, as demonstrated in models of arthritis and
multiple sclerosis (24, 25). RORC2 expression is also limited to
CCR6+ populations enriched for Th17 and Th17/1 cells. To
clearly distinguish viable Th17 and Th1 cells ex vivo we used
a cytokine capture technique, avoiding the potential for epige-





































Fig. 4. CD161 expression may identify Th1 cells with a Th17 ancestry. (A) Representative ﬂow cytometric analysis of SFMC comparing CD161 expression with
IL-17 and IFN-γ production, gated on CD4+ T cells. Numbers in plots indicate percentage of parent population. (B) CD161 expression in gated synovial Th17
cells, Th17/1 cells, and Th1 cells (n = 4). (C) IL-17+ cells expressing CD161 from healthy controls were sorted and cultured in the presence of IL-12. (Upper Left)
Dot plot of intracellular IL-17 and IFN-γ detected on day 6 of culture and CD161 expression in the same cells (indicated by arrows) gated on Th17, Th1, and
Th17/1 subpopulations (n = 3). The dotted line represents isotype control and numbers in histograms indicated percentage of cells expressing CD161. (D)
Summary of three independent experiments, showing CD161 expression on gated subpopulations as in C and (last column) percentage of control CD161−
population expressing CD161 after culture in the same conditions as C. Control data for CD161+ Th17 cells stimulated without IL-12 were equivalent to results
seen in Fig. 3B. (E) Cytokine-expressing synovial CD4+ T cells were sorted into IL-17+, CD161+IFN-γ+, and CD161-IFN-γ+ populations. RORC2 and IL-17 mRNA
expression in sorted synovial populations is shown. *P < 0.05. Bars represent mean values (±SEM, n = 3). (F) Mean percentage (±SEM, n = 6) of above
populations expressing CCR6 protein detected by ﬂow cytometry. (G) (Left) Mean (±SEM, n = 4) IL-23R mRNA expression in sorted populations as in E:
Representative ﬂow cytometric analysis of SFMC IL-23R expression (or isotype) and IL-17 production, with plots gated on CD4+ T cells. (Right) Mean per-
centage (±SEM, n = 6) of IL-17+, CD161+IFN-γ+, and CD161-IFN-γ+ populations expressing IL-23R protein, detected by ﬂow cytometry. (H) Three hundred
eighty-three PCR products for TRBV18 from patient 1 were cloned and sequenced. Sequence results are illustrated as pie charts with colored segments to
indicate clones that overlap between populations (limited to IL-17+ and CD161+ Th1 populations). Numbers indicate clone size as a percentage of total
number sequenced for that cell population. Nonoverlapping clones (gray) and unique sequences (white) for all three populations are shown. Full TCR
sequences across the CDR3 junction are listed in Table S1.
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long-term in vitro culture (26). Puriﬁed synovial Th1 cells have
signiﬁcantly higher T-bet mRNA expression than Th17 cells,
whereas Th17/1 cells are intermediate between Th17 and Th1.
T-bet expression has been linked to autoimmune pathology, in-
dependent of IFN-γ, and may confer a greater pathogenicity to
synovial Th17/1 compared with Th17 cells (27). Interestingly,
clones derived from the gut of patients with IBD did not show
these differences, T-bet expression being equal in all three sub-
sets (12). With respect to Th17 transcription factors, our results
show that RORC2 expression was more speciﬁcally linked to
Th17 and Th17/1 cells than either IRF4 or AHR. This ﬁnding
may reﬂect a role for IRF4 and AHR that is permissive but not
critical to Th17 differentiation (19, 28).
Our study is supported by others of human autoimmune dis-
ease where Th17/1 cells are found to be enriched at the disease
site (7, 11, 12), more commonly than their murine counterparts
(2, 10, 14). The mechanism(s) that lead to Th17/1 enrichment are
still unknown. Some reports implicate antigen-presenting cells
in promoting Th17/1 responses, through cell contact-dependent
mechanism(s) (29, 30). We explored the role of soluble mediators
in promoting Th17/1 cells at the inﬂammatory site. We show that
synovial ﬂuid is distinct from the plasma of arthritis patients, with
synovial ﬂuid having high concentrations of IL-12 but low levels of
total TGF-β, of which the majority detected may be latent TGF-β
rather that its biologically active form.
When recapitulated in vitro, the high IL-12, low TGF-β envi-
ronment promotes the conversion of Th17 toward a Th17/1
phenotype. Although IL-23 may contribute to this plasticity in
murine studies (13), we and others do not detect IL-23 within the
joint (31) or its secretion by resident monocytes (29). To our
knowledge evidence for Th17 plasticity has thus far been limited
to in vitro studies in humans or murine models (12, 14). We have
extended these ﬁndings to patients with autoimmune arthritis,
showing signiﬁcant overlap in TCR clonality between Th17 and
Th17/1 cells taken directly from the inﬂamed joint. We propose
that Th17 cells recruited to this chronic inﬂammatory site can
convert to Th17/1 in response to local IL-12. Given the domi-
nance of memory T cells (32) in the joint, it is unlikely that Th17
and Th17/1 clones arise from a common naive T-cell precursor in
situ. Conversion may occur within local lymph nodes, but would
require concomitant migration of both Th17 and Th17/1 cells to
the joint to be detected as shared clones. Th17 cells in culture
may lose IL-17 expression, possibly through a Th17/1 interme-
diate, to gain a Th1 phenotype (13, 14). CD161 appears to track
this conversion, marking Th17 cells that switch to a Th1 phe-
notype in vitro. This process, if consistent in vivo, would explain
our ﬁnding of elevated RORC2, CCR6, and IL-23R expression
in CD161+ Th1 cells from the joint compared with CD161−
Th1. Furthermore, all of the T-cell clones (deﬁned by nucleo-
tide sequence across TRBV CDR3), which we demonstrated
were shared between IL-17+ and Th1 cells, are restricted to the
CD161+ population. The frequency of overlap between the
Th17 and Th1 repertoires is relatively low. Thus this result may
reﬂect an infrequent conversion of Th17 to CD161+ Th1 cells
within the synovial compartment. Alternatively, CD161+ Th1
cells may arise outside of the Th17 pathway and CD161 ex-
pression may relate to pathological events independent of IL-17.
One ligand of CD161, PILAR, is highly enriched within the joint
(33) and stabilizes effector T cells, through increased expression
of the anti-apoptotic Bcl-xL. Binding of PILAR to CD161 leads
to secretion of inﬂammatory chemokines and IFN-γ. Finally it is
of note that none of the CD161− clones in our study overlap with
either CD161+ or IL-17+ cells, suggesting separate origins for
the CD161− Th1 population.
One limitation of the in vitro data in our study is that con-
taminating Th17/1 or Th1 cells may expand in response to IL-12
and account for some of the Th17 plasticity seen (Fig. 3B).
However, taken together with the expression of Th17-signature
genes (IL-23, CCR6, RORC2) in CD161+ Th1 synovial cells
ex vivo and the overlap in TCR sequence between Th17 and
CD161+ Th1 cells, this result strongly suggests that conversion
of human Th17 to Th1 is a real phenomenon.
The implications of Th17 conversion to Th17/1 or Th1 and the
consequent colocalization of IL-17 and IFN-γ in the inﬂamed
joint are intriguing. The relationship between IL-17 and IFN-γ is
a complex one, IFN-γ being protective in some models by reg-
ulating Th17 differentiation and pathogenic in others (34). Trials
of recombinant human IFN-γ have failed to provide signiﬁcant
clinical beneﬁt in rheumatoid arthritis, questioning a role for
IFN-γ as a regulator of Th17-mediated disease in human arthritis
(35). In psoriasis, IFN-γ from Th1 cells acts on resident APC to
promote the induction of Th17 as well as their recruitment to the
target site, through the production of CCL20 (36). In the context
of our ﬁndings, we propose that there may be a cycle of positive
feedback whereby Th17 are recruited to the joint and convert to
Th17/1 or Th1 in response to local IL-12, and the resulting IFN-γ
secreted promotes further recruitment of Th17 by virtue of the
secreted CCL20.
Our study provides unique insights into the biology and reg-
ulation of Th17/1 cells, with evidence for Th17 plasticity toward
both Th17/1 and Th1 cells in the joints of patients with arthritis.
It shows that Th17/1 enrichment in the chronically inﬂamed site
may be driven by a permissive environment that promotes Th17
plasticity. It is possible that this process of conversion varies in
different subtypes of arthritis, and if found to be accelerated in
rheumatoid arthritis it may explain the enrichment of Th1 but
not Th17 cells seen in the joints of patients with this disease (9).
If Th17 plasticity accounts, at least in part, for the sizeable pop-
ulation of CD161+ Th1 cells found at the inﬂamed site, we
predict that biologic treatments targeting the generation of Th17
may have the additional beneﬁt of also attenuating effector
Th17/1 and Th1 populations.
Materials and Methods
Patients and Samples. Samples from 59 children with JIA (37) and 17 healthy
controls were included in this study. The study had approval from the local
ethical review committee and full informed consent was obtained from
patients/parents. PBMC were isolated by density centrifugation. For prepa-
ration of SFMC, samples were ﬁrst treated with hyaluronidase (Sigma-
Aldrich) at 10 units/mL for 30 min at 37 °C, before density gradient isolation.
Cell Sorting and Flow Cytometry. Cell sorting was performed on the BD
FACSAria (BD PharMingen). Antibodies used are listed in SI Materials and
Methods. For sorting of SFMC by chemokine receptor expression of CCR4
and CCR6, cells were ﬁrst gated on the CD4+CD25− lymphocytes. For analysis
of cytokine production by T cells, SFMC or PBMC were cultured for 5 h in the
presence of 50 ng/mL PMA and 500 ng/mL ionomycin and cell supernatants
were harvested or for 3 h in the presence of 5 μg/mL Brefeldin A (all from
Sigma-Aldrich) before intracellular cytokine detection by ﬂow cytometry (7).
To capture cytokine-expressing cells, PBMC or SFMC were enriched for CD4+
T cells using negative selection magnetic beads (Stemcell Technologies) and
stimulated for 2 h with PMA (10 ng/mL) and ionomycin (1 μg/mL) (38). IL-17–
and IFN-γ–secreting CD4+ T cells were detected according to manufacturer’s
instructions (Miltenyi Biotec) and sorted by ﬂow cytometer. Purity was
assessed by detecting intracellular cytokines after overnight incubation in
Brefeldin A. Flow cytometric data were collected on a LSRII (BD PharMin-
gen); 1 × 105 events were collected for each condition. Data were analyzed
using FlowJo (Treestar).
Cell Culture. Sorted cells were cultured in IMDM, 10% FCS (Invitrogen) in the
presence of IL-12 (10 ng/mL; R&D Systems) to track CD161 expression or, in
some experiments, serum-free “Ex-vivo15” medium (Lonza) in the presence
of IL-2 (50 IU/mL; Roche) and combinations of TGF-β (5 ng/mL; R&D Systems),
IL-6 (BD PharMingen), and IL-12. On day 6 intracellular IL-17 and IFN-γ ex-
pression was detected by ﬂow cytometry after restimulation with PMA and
ionomycin in the presence of Brefeldin A. A live/dead discriminant dye was
used in accordance with manufacturer’s instructions (Invitrogen).









Multiplex Immunoassay. Cell supernatants were analyzed for cytokines using
a multiplex immunoassay as described (39). TGF-β and IL-21 were analyzed by
ELISA (R&D Systems) in platelet-depleted synovial supernatants and plasma
from JIA patients.
PCR. Generation of cDNA and RT-PCR was performed as described (40). See SI
Materials and Methods for details.
T-Cell Receptor Analysis by Spectratyping and Sequencing. Complementarity
determining region-3 (CDR3) TCR spectratyping was performed as previously
described (41). TRBV PCR products were cloned using a TOPO-TA cloning
strategy (Invitrogen) and ampliﬁed using M13 primers. Sequencing was
performed on a 3730xl capillary sequencer and analyzed using Sequencher
(Gene Codes).
Statistical Analysis.Data were analyzed using SPSS v16.0 and Graphpad Prism.
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